Discontinuation of statin therapy due to muscular side effects: A survey in real life

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 9, 2013, Pages 871-875

  Rosenbaum, D ^a,b   Dallongeville, J ^c   Sabouret, P ^d   Bruckert, E ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIV LILLE   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Dyslipidemia; Muscular symptoms; Real life survey; Side effects; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; ARTICULATION PAIN; DAILY LIFE ACTIVITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FISHER EXACT TEST; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE CRAMP; MUSCLE DISEASE; MUSCLE METABOLISM; MUSCLE RIGIDITY; MUSCLE WEAKNESS; MYALGIA; OBSERVATIONAL STUDY; PAIN; PALLIATIVE THERAPY; POSTMARKETING SURVEILLANCE; QUESTIONNAIRE; RIGIDITY; SARCOPENIA; TELEPHONE INTERVIEW; TENDINITIS; WEAKNESS;

DYSLIPIDEMIA; MUSCULAR SYMPTOMS; REAL LIFE SURVEY; SIDE EFFECTS; STATINS;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MOTOR ACTIVITY; MUSCLE CRAMP; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULOSKELETAL DISEASES; PAIN; PYRIMIDINES; PYRROLES; QUESTIONNAIRES; RISK FACTORS; SIMVASTATIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84884130876     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.04.012     Document Type: Article

References (20)

1. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. The New England Journal of Medicine 1998;339:1349-1357.
2. Pedersen T.R., Kjekshus J., Berg K., Haghfelt T., Faergeman O., Faergeman G., et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
3. Bonovas S., Nikolopoulos G., Sitaras N.M. Efficacy and safety of more intensive lowering of LDL cholesterol. Lancet 2011, 377:715-716. 715; author reply.
4. Bertolini S., Bon G.B., Campbell L.M., Farnier M., Langan J., Mahla G., et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997, 130:191-197.
5. Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. The New England Journal of Medicine 2002, 346:539-540.
6. Lambrecht L.J., Malini P.L. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group. Acta Cardiologica 1993, 48:541-554.
7. Ballantyne C.M., Corsini A., Davidson M.H., Holdaas H., Jacobson T.A., Leitersdorf E., et al. Risk for myopathy with statin therapy in high-risk patients. Archives of Internal Medicine 2003, 163:553-564.
8. Sinzinger H., Wolfram R., Peskar B.A. Muscular side effects of statins. Journal of Cardiovascular Pharmacology 2002, 40:163-171.
9. Franc S., Dejager S., Bruckert E., Chauvenet M., Giral P., Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovascular Drugs and Therapy/Sponsored by the International Society of Cardiovascular Pharmacotherapy 2003, 17:459-465.
10. Haute Autorité de Santé Efficacité et efficience des hypolipémiants: une analyse centrée sur les statines. Juillet 2010.
11. Bruckert E., Hayem G., Dejager S., Yau C., Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovascular Drugs and Therapy/Sponsored by the International Society of Cardiovascular Pharmacotherapy 2005, 19:403-414.
12. Abd T.T., Jacobson T.A. Statin-induced myopathy: a review and update. Expert Opinion on Drug Safety 2011, 10:373-387.
13. Pasternak R.C., Smith S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002, 106:1024-1028.
14. Chatzizisis Y.S., Vaklavas C., Giannoglou G.D. Coenzyme Q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy?. The American Journal of Cardiology 2008, 101:1071.
15. Jackevicius C.A., Mamdani M., Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA: the Journal of the American Medical Association 2002, 288:462-467.
16. Johnson S.S., Paiva A.L., Cummins C.O., et al. Transtheoretical model-based multiple behavior intervention for weight management: effectiveness on a population basis. Preventive Medicine 2008, 46:238-246.
17. Gadarla M., Kearns A.K., Thompson P.D. Efficacy of rosuvastatin (5mg and 10mg) twice a week in patients intolerant to daily statins. The American Journal of Cardiology 2008, 101:1747-1748.
18. Athyros V.G., Tziomalos K., Kakafika A.I., Koumaras H., Karagiannis A., Mikhailidis D.P. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10mg) for statin intolerant high-risk patients. The American Journal of Cardiology 2008, 101:483-485.
19. Glueck C.J., Budhani S.B., Masineni S.S., Abuchaibe C., Khan N., Wang P., et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. Current Medical Research and Opinion 2011, 27:1683-1690.
20. Thompson P.D., Parker B.A., Clarkson P.M., et al. A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. Preventive Cardiology 2010, 13:104-111.